相关实验视频

Updated: Jan 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

2025年细胞免疫疗法用于血细胞疾病的更新

Ece Vural¹, Merak Beksaç²

¹Yüksek Lisans University; Ankara Liv Hospital, Department of Hematology, Ankara, Türkiye.

Turkish journal of haematology : official journal of Turkish Society of Haematology

|December 22, 2025

概括

化学抗原受体T细胞 (CAR-T) 疗法对多发性骨髓瘤 (MM) 和其他血液癌症有前途. 尽管面临挑战,但正在进行的研究和BCMA和GPRC5D等新目标正在扩大CAR-T治疗选择.

科学领域:

血液学血液学血液学
免疫疗法是一种免疫疗法.
在瘤学瘤学.

背景情况:

尽管在多发性骨髓瘤 (MM) 治疗方面取得了进展,但对高风险患者仍需要新的治疗方法.
化学抗原受体T细胞 (CAR-T) 疗法已成为MM治疗的重大进展.

研究的目的:

审查当前的CAR-T目标和针对多发性骨髓瘤和相关疾病的新兴疗法.
讨论CAR-T细胞疗法的挑战和未来方向.

主要方法:

对针对BCMA,GPRC5D和其他分子的CAR-T细胞疗法的现有文献的审查.
对已批准和正在研究的CAR-T产品的临床试验数据和现实世界的证据进行分析.
探索新的CAR-T设计,包括双重定位和学术CAR-T倡议.

主要成果:

经FDA批准的抗BCMA CAR-T疗法 (Ide-cel,Cilta-cel) 在复发性/耐药性MM (RRMM) 中显示出有效性.
新兴的CAR-T目标 (GPRC5D,FcRH5,SLAMF7,TACI) 和新的构造 (Fast-CAR,in-vivo扩散) 正在调查中.
学术CAR-T疗法证明了与商业产品相比的有效性和安全性,提供了成本效益.
卡特-T研究正在扩展到燃烧的MM (SMM) 和AL粉症,对高风险的SMM和AL粉症有希望的结果.

结论:

卡特-T疗法是MM和其他血液恶性瘤的不断发展和有效的治疗方式.
通过组合疗法和新策略克服挑战将进一步提高CAR-T的疗效.
预计未来的CAR-T应用将在早期疾病阶段出现,基因编辑技术如CRISPR将发挥关键作用.

关键词:

由T淋巴细胞进行抗原识别.免疫学免疫学免疫学分子血液学分子血液学骨髓瘤和其他血细胞失分症.新生病是什么?新生病是什么?

更多相关视频

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...